TARSUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
TARSUS PHARMACEUTICALS, INC. (TARS) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $0 as of 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2024-05-08
- 2024-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $225.00K.
- 2023-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $73.00K.
- 2023-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $109.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $225.00K 10-Q · filed 2024-05-08 |
| 2023-09-30 | $73.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $109.00K 10-Q · filed 2023-11-09 |
| 2023-03-31 | $91.00K 10-Q · filed 2024-05-08 |
| 2022-12-31 | $108.00K 10-Q · filed 2024-05-08 |
| 2022-09-30 | $246.00K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $264.00K 10-Q · filed 2023-11-09 |
| 2022-03-31 | $418.00K 10-Q · filed 2023-11-09 |
| 2021-12-31 | $663.00K 10-Q · filed 2023-11-09 |
| 2021-09-30 | $1.50M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $1.08M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $1.23M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |